AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04921293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet + placebo
Description: A standard diet incorporating current recommendations (low in sodium and low in liquids) for heart failure patients.
Study NCT04925336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nociceptive stimulation
Description: These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer.
Study NCT06394726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise İntervention
Description: Aerobic and Core Stabilization Exercise Intervention
Study NCT04778293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Description: An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized, in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
Study NCT05081921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MesoCellA-Ortho administration
Description: Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups.
Study NCT05081921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HA administration
Description: Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups.
Study NCT05405868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinomide
Description: Nicotinamide tablets (750mg)
Study NCT05405868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study NCT05783193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGIR (Traditional Gastrointestinal Remedy)
Description: TGIR botanical formulation
Study NCT05783193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT06355492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality goggles (VR )
Description: Patients will take buccal infiltration anaethesia using (Virtual reality goggles) that properly adjusted around the patient's head and in front of his/her eyes.
Study NCT05191342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay for PCSK9
Description: Enzyme-linked immunosorbent assay for plasma PCSK9
Study NCT06355492 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: regular screen
Description: Patients will take buccal infiltration anaethesia using (regular screen ).
Study NCT05834842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unisalud
Description: The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention.
Study NCT05346523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isabel Pro - The DDx generator (CDDS)
Description: Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
Study NCT06322797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. First, the resting motor threshold was measured for each patient. At the lowest stimulus output, a stimulus was applied to the M1 cortex of the uninjured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb. The resting motor threshold was defined as the intensity required to generate a motor-induced potential of > 50 uV in the contralateral abductor pollicis brevis muscle at least 5 out of 10 times with 30 s of inter-stimulus time interval.~Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min.
Study NCT06322797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. After identifying the brain site that is activated during finger tapping during fMI, Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min. the resting motor threshold was measured for each patient at target brain site.
Study NCT06446206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
Description: Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
Study NCT00012896 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Care + Educational (AV Materials)
Study NCT06118346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Female-Specific Cognitive Behavioral Therapy (FS-CBT)
Description: FS-CBT is a unique 12-session weekly group CBT treatment designed for women Veterans with AUD and/or risky drinking, and provides (1) AUD interventions, (2) general female-specific content, (3) female-Veteran content, (4) wellness and self-care, and (5) a novel 24/7 social support for abstinence discussion mobile app.
Study NCT06118346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
Study NCT06118346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
Study NCT05372874 — intervention group
Intervention type: DRUG
Intervention: Direct Acting Antivirals
Description: hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
Study NCT05506722 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Testes shocker
Description: It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
Study NCT05506722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Testes shocker
Description: It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
Study NCT05329298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-361175
Description: Subjects will receive BPI-361175 until disease progression
Study NCT04785508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscolar tape
Description: neuromuscalar tape application in decompression technique (hand and arm)
Study NCT04785508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: antigravity arm position
Description: antigravity arm position
Study NCT05368441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
Study NCT05368441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
Study NCT06322797 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: In Sound Mode, no actual stimulation is applied, and 20 minutes of treatment is performed like other experimental groups.
Study NCT05966220 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hip surgery with FH Ortho devices
Description: This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons.
Study NCT05266820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: For the experimental group, the intervention was thalidomide（100mg PO Bid)
Study NCT05266820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102
Study NCT05266820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102
Study NCT05366465 — intervention group
Intervention type: OTHER
Intervention: SMA adult patients
Description: An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
Study NCT04781036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4%Chlorhexidine
Description: 4%Chlorhexidine was given to participants with foot odor for 2 weeks
Study NCT03814941 — intervention group
Intervention type: OTHER
Intervention: paper-based anesthesia record
Description: to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record
Study NCT03814941 — intervention group
Intervention type: OTHER
Intervention: electronic documents
Description: to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
Study NCT02925806 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review
Study NCT05667350 — intervention group
Intervention type: OTHER
Intervention: Blood drawing
Description: Blood drawing before anti-cancer therapy
Study NCT05667350 — intervention group
Intervention type: OTHER
Intervention: Blood drawing
Description: Blood drawing before radical treatment
Study NCT06370039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution
Study NCT06370039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Ophthalmic Solution
Study NCT04933526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumatinib
Description: Flumatinib 600mg QD orally form 1 to 12 months
Study NCT04608877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take 5 and Audio Clip
Description: Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
Study NCT04608877 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Take 5 Only
Description: Parent will only receive the 5 discrete safety steps for infant crying
Study NCT04339270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithropycin according to symptoms
Description: Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score> 70, management is not changed.
Study NCT04339270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin according to rheology or symptoms
Description: Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) > 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score> 70, management is not changed.
Study NCT05983094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: Utidelone injection 30mg/m2, on days 1-5 of each cycle
Study NCT04933526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dasatinib
Description: Dasatinib 100mg QD orally form 1 to 12 months
Study NCT05983094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area under curve(AUC)6, iv, was administered on day 1
Study NCT05983094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75mg/m2 was administered on day 1
Study NCT05983094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles
Study NCT05983094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles
Study NCT04884607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes
Description: * Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~* Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart.
Study NCT05203380 — intervention group
Intervention type: DRUG
Intervention: dupilumab
Description: Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
Study NCT03940807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11.25mg GnRH agonist
Description: Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.
Study NCT03940807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 mg GnRH agonist
Description: Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.
Study NCT03940807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 µg transdermal oestradiol
Description: Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
Study NCT05533255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)
Description: Composite resin at room temperature is used.
Study NCT05533255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)
Description: Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
Study NCT05577091 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
Description: Intratumoral or intraventricular administration via Ommaya reservoir.~Dose level 0: 1×10\^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients.~Dose level 1: 1×10\^8/ 5×10\^6 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10\^6 cells.~In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and the subsequent doses will be administered weekly.~Dose level 2: 5×10\^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side effects could have occurred in the 1×10\^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study.
Study NCT06452693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3038 injection/placebo
Description: TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
Study NCT06452693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleotide drugs Control group
Description: Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
Study NCT05831618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Visuo-Vestibular training
Description: Dynamic motor activitites aimed to enhance the visuo-vestibular interaction and the sensorial reweighting will be performed for the Interactive Visuo-Vestibular training group.
Study NCT05831618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular rehabilitation training
Description: Dynamic motor activitites aimed to enhance vestibular reflexes will be performed for the vestibular rehabilitation group
Study NCT04831671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Approach - Infra-patella nailing
Description: The intra-medullary nail will be introduced via an infra-patella incision.
Study NCT05072665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
Description: HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
Study NCT04831671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical Approach - Supra-patella nailing
Description: The intra-medullary nail will be introduced via a supra-patella incision.
Study NCT04946695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telefisio India
Description: Implement telephysiotherapy programmes in low-resource areas.
Study NCT05909748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEMINUS Transcatheter Aortic Valve Implantation system
Description: Implantation of the GEMINUS Transcatheter Aortic Valve Implantation system
Study NCT05941169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Nephrectomy
Description: The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN
Study NCT05391568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Dry Needling
Description: Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle.